Could one curcuminoid metabolite be more important than curcuminoid itself?
With the Natural Products Expo West trade show just two weeks away, Sabinsa (East Windsor, NJ) is already introducing manufacturers to Curcumin C3 Reduct, its latest development in highly absorbable curcumin.
Curcumin is the active component of turmeric spice. A wealth of research supports its role as a dietary antioxidant, and as a potential tool to fight cancer, heart failure, lung damage, and a host of other health complications.
Sabinsa customers are probably familiar with the company’s longstanding Curcumin C3 Complex, which is based on curcuminoids; but the Curcumin C3 Reduct represents a change in understanding of how curcumin is absorbed by the body.
Curcumin C3 Reduct…is the result of recent research into metabolites of curcuminoids that have unraveled the role of tetrahydrocurcuminoids as not only the major metabolites but also pharmacologically superior to curcuminoids themselves. It is not the curcumin, but its metabolite tetrahydrocurcumin (THC), which is responsible for its biological function in the body.
Sabinsa adds that these tetrahydrocurcuminoids are better absorbed in the gut than their parent curcuminoids. The company is even recommending this new product at 400 mg daily compared to the 1500 mg daily suggested for Curcumin C3 Complex.
Curcumin C3 Reduct is standardized for 95% THC.
Another breakthrough with Sabinsa’s new curcumin ingredient is that it’s white-as in not the deep natural yellow of turmeric, which presented a lot of challenges for Sabinsa customers. The extra aesthetic benefit could really drive interest in this curcumin for use in beverages.
Visit Sabinsa at Expo West, booth #310, for more details on its novel curcumin ingredient.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.